CST, 4132T, Cyclin E2 Antibody

Polyclonal Antibody for studying Cyclin E2. Validated for Western Blotting. Available in 2 sizes. Highly specific and rigorously validated in-house, Cyclin E2 Antibody (CST #4132) is ready to ship. Product Usage Information Western Blotting: 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting Specificity / Sensitivity Cyclin E2 Antibody detects endogenous levels of total cyclin E2 protein. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy-terminus of human cyclin E2. Antibodies are purified by protein A and peptide affinity chromatography. Background Cyclin E1 and cyclin E2 can associate with and activate CDK2 (1). Upon DNA damage, upregulation/activation of the CDK inhibitors p21 Waf1/Cip1 and p27 Kip1 prevent cyclin E/CDK2 activation, resulting in G1/S arrest. When conditions are favorable for cell cycle progression, cyclin D/CDK4/6 phosphorylates Rb and is thought to reduce the activity of p21 Waf1/Cip1 and p27 Kip1, allowing subsequent activation of cyclin E/CDK2 (1,2). Cyclin E/CDK2 further phosphorylates Rb to allow progression into S-phase, where cyclin E/CDK2 is thought to phosphorylate and activate multiple proteins involved in DNA synthesis (2,3). Turnover of cyclin E is largely controlled by phosphorylation that results in SCFFbw7-mediated ubiquitination and proteasome-dependent degradation (4,5). Cyclin E1 is phosphorylated at multiple sites including Thr62, Ser88, Ser72, Thr380, and Ser384, and is controlled by at least two kinases, CDK2 and GSK-3 (6,7). Alternate Names CCNE2; CYCE2; cyclin E2; Cyclin-E2; G1/S-specific cyclin E2; G1/S-specific cyclin-E2 Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 48 SOURCE: Rabbit